K Pharma,Inc.

2026/08/19 Updated
Market Cap: $54.7M (¥8.7B)
Stock Price: $4.71 (¥751)
Exchange Rate: 1 USD = ¥159.49

Financial Summary for the Second Quarter of the Fiscal Year Ending December 2026 (Interim) [Japanese GAAP] (Consolidated)

Disclosure of the results for the second quarter (mid-year) of the fiscal year ending December 2026. Highlights sales, operating income, ordinary income, net income, and the financial position. The balance sheet includes details of current assets, fixed assets, liabilities, capital structure, and cash flows. While the full-year outlook is disclosed in a separate document, this summary notes interim results and year-over-year variances.

Importance:
Page Updated: August 13, 2026
IR Disclosure Date: August 13, 2026

Key Figures

  • Sales: Unknown (no notation)
  • Operating income: Unknown (no notation)
  • Ordinary income: Unknown (no notation)
  • Net income: Unknown (no notation)
  • Total assets: Unknown
  • Total equity: Unknown
  • Cash and cash equivalents: Unknown

AI要約

Performance Overview

This financial summary is a document disclosing the results and financial position for the second quarter (mid-year) of the fiscal year ending December 2026. The main indicators such as sales, operating income, ordinary income, and net income are listed as 'Unknown' in the body, and quarterly progress and YoY changes are not explicitly stated in the narrative. Instead, itemized amounts for the assets, liabilities, and net assets sections are presented, with notes on the composition and trends of current assets, fixed assets, current liabilities, fixed liabilities, and net assets. Cash flow items are shown in a table with explanations of the factors driving changes in cash.

Outlook and Risks

The financial summary presents interim results and the breakdown of financial position, but the full-year forecast and future performance outlook require reference to a separate document or next disclosure. The summary includes information on current cash plans and liquidity, major funding requirements and sources of funds, and comments on the continuity of funding stability. Investors should note that the visibility of full-year projections is currently unclear and should monitor forthcoming updates.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Kei Pharma Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →